Tag: #geneediting

Intellia’s one-time CRISPR therapy cuts hereditary angioedema attacks 87% in Phase 3; rolling FDA filing started

Phase 3 trial of Intellia's one-time in‑vivo CRISPR therapy lonvo‑z cut hereditary angioedema attacks 87%; company began rolling FDA filing.

$NTLA, #crispr, #geneediting, #biotech, #hereditaryangioedema, #intellia

FDA Issues Draft Guidance on Using Next-Generation Sequencing to Assess Genome-Editing Safety

FDA's draft guidance explains how developers should use next-generation sequencing to detect off-target edits and chromosomal damage before human trials.

#geneediting, #fda, #ngs, #genetherapy